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ABSTRACT
Objective We sought to test the hypothesis that Polygenic 
Risk Scores (PRSs) have strong capacity to discriminate cases 
of ankylosing spondylitis (AS) from healthy controls and 
individuals in the community with chronic back pain.
Methods PRSs were developed and validated in 
individuals of European and East Asian ethnicity, using 
data from genome- wide association studies in 15 585 
AS cases and 20 452 controls. The discriminatory values 
of PRSs in these populations were compared with other 
widely used diagnostic tests, including C- reactive protein 
(CRP), HLA- B27 and sacroiliac MRI.
Results In people of European descent, PRS had high 
discriminatory capacity with area under the curve (AUC) 
in receiver operator characteristic analysis of 0.924. This 
was significantly better than for HLA- B27 testing alone 
(AUC=0.869), MRI (AUC=0.885) or C- reactive protein 
(AUC=0.700). PRS developed and validated in individuals 
of East Asian descent performed similarly (AUC=0.948). 
Assuming a prior probability of AS of 10% such as in patients 
with chronic back pain under 45 years of age, compared with 
HLA- B27 testing alone, PRS provides higher positive values 
for 35% of patients and negative predictive values for 67.5% 
of patients. For PRS, in people of European descent, the 
maximum positive predictive value was 78.2% and negative 
predictive value was 100%, whereas for HLA- B27, these 
values were 51.9% and 97.9%, respectively.
Conclusions PRS have higher discriminatory capacity 
for AS than CRP, sacroiliac MRI or HLA- B27 status alone. 
For optimal performance, PRS should be developed for 
use in the specific ethnic groups to which they are to be 
applied.
INTRODUCTION
Ankylosing spondylitis (AS) affects approximately 
0.2%–0.6% of individuals of European descent and 
Chinese.1 2 Early treatment with biologic therapies 
in those with more severe forms of the disease 
achieves more effective clinical responses3 and 
probably reduces the rate joint fusion in the long 
term.4 However, other causes of chronic back pain 
are common in the community, and AS is respon-
sible for only a minority of these cases. It can be 
difficult to distinguish AS from other causes of back 
pain, particularly early in the disease with the conse-
quence that the diagnosis of AS is often significantly 
delayed; many surveys undertaken in a variety of 
different health systems suggest an average delay 
of 6–10 years.5–7 A recent North American survey 
reported that fewer than half (37.1%) of patients 
with AS reported that they were correctly diag-
nosed within 1 year of seeking medical attention, 
and 32.8% waited more than a decade to receive 
the diagnosis.7 Population surveys suggest that as 
many as 80% of cases in the community remain 
Key messages
What is already known about this subject?
 ► HLA- B27 testing is widely used in the diagnostic 
pathway in ankylosing spondylitis (AS), but only 
captures a moderate proportion (~20%) of the 
overall genetic risk for the disease.
What does this study add?
 ► Polygenic Risk Scores (PRSs) for AS perform 
better than HLA- B27 testing and other standard 
diagnostic tests employed in AS including 
C- reactive protein measurement and MRI 
scanning.
How might this impact on clinical practice or 
future developments?
 ► PRS for AS should be used to assist diagnosing 
AS among patients with chronic back pain.
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undiagnosed8 and therefore may not receive appropriate effec-
tive treatment. There is thus a great need for improved testing to 
improve early accurate diagnosis.
Currently, the most widely used tests for AS in those with 
chronic back pain are measurements of acute phase reactants, 
such as erythrocyte sedimentation rate and C- reactive protein 
(CRP), genetic testing for HLA- B27 and imaging—either plain 
radiographs or MRI of the sacroiliac joints.9 However, each of 
these tests has limitations. In brief, acute phase reactants and 
MRI are only positive after disease develops and are therefore 
not useful for predicting disease risk. Acute phase reactants 
have only moderate sensitivity and specificity, particularly in 
early disease. MRI is expensive and is not universally avail-
able. Genetic factors are the major determinants of the risk of 
developing AS, with heritability assessed in twins of >90%.10 11 
Although HLA- B27 alone contributes 20% of the variation in 
disease risk,12 the remainder of the genetic risk is determined by 
thousands of common genetic variants, each of which has only 
a very small effect. Polygenic Risk Scores (PRS) use combina-
tions of hundreds to thousands of genetic variants to quantify 
an individual’s genetic risk of disease. Unlike HLA- B27 testing 
which is categorical or dichotomous in outcome, PRS are contin-
uous measures. They are of particularly strong predictive value 
for low- frequency diseases with high heritability,13 such as AS. 
Here, we describe the development and validation of PRS for AS 
in two different ethnic groups and compare its performance to 
standard screening or diagnostic tests.
METHODS
Study population
AS was defined according to the modified New York criteria.14 
Following genotyping quality control, there were 8244 cases 
and 14 274 controls of western European descent; 6001 cases 
and 4493 controls of East Asian (Chinese) descent; and 1340 
cases and 1685 controls of Turkish and Iranian origin, respec-
tively. Written informed consent was obtained from all cases, 
with approval from the relevant research ethics authorities at 
each participating centre. Cohort details are provided in online 
supplemental table S1.
Genetic data
Samples were genotyped using the Illumina Core- Exome SNP 
genotyping microarray, according to the manufacturer’s recom-
mendations (chip versions used per cohort are provided in online 
supplemental table S1). Bead intensity data were processed 
and normalised for each sample, and genotypes called, using 
Genome Studio V.2.0 software (GenomeStudio Software Down-
loads ( illumina. com)). Standard quality control measures as 
outlined in the Supplementary Methods were applied including 
identification and exclusion of cryptic- related samples, exclu-
sion of samples with an outlying heterozygosity rate (3 SD from 
the mean in each cohort) or excess missingness (>5%). Single 
nucleotide polymorphisms (SNPs) with genotyping missing rate 
>2%, p value of Hardy- Weinberg equilibrium test <1×10-6, or 
with allele frequency <1% were removed. Population stratifi-
cation was accessed using Shellfish (http://www. stats. ox. ac. uk/~ 
davison/ software/ shellfish/ shellfish. php). PRS analyses were 
performed with and without inclusion of principal components 
and gender as covariates. Results including principal compo-
nents and gender as covariates are reported in online supple-
mental table S2 and are very similar to the results not including 
these covariates.
HLA- B27 imputation was performed using SNP2HLA, using 
a deep sequencing Chinese reference panel (n=10 689)15 for 
East Asian samples and Type 1 Diabetes Genetics Consortium 
(n=5225) panel of combined HLA types and MHC SNP geno-
types for all other subjects.16
PRS were calculated for each individual using the adaptive 
MultiBLUP algorithm (implemented in the software LDAK 
V.5.0).17 LDAK first divides the genetic data into chunks of size 
75 000 bp and then performs association test for all the chunks 
and thinned out SNPs in strong linkage disequilibrium. The 
significant chunks with p value <1×10-5 and all adjacent chunks 
with p value <0.01 are merged into regions. Then the variance 
components and effect size of SNPs are estimated, and the effect 
size of the SNPs used to calculate the PRS. A 10- fold cross- 
validation analysis was performed as internal validation; a sepa-
rate external validation was performed in the British and North 
American subjects, as well as through comparison of perfor-
mance of PRS trained in either European descent or East Asian 
subjects, then validated in a separate ethnic group. In regard to 
cross- validation studies, the case–control cohort being studied 
is divided into 10 equal folds randomly with same case–control 
ratio. Nine folds of samples were used as a training set and the 
remaining fold of samples was retained as the validation data 
for testing the model generated by the training set. The process 
was repeated 10 times, with each of the 10- folds used only 
once as the validation data. The out- of- fold predictions based 
on the effect sizes of the selected SNPs were obtained for the 
test fold. All the predictions of 10 test folds were merged, after 
which statistical analysis was performed using all out- of- fold 
test set predictions to maximise sample size for internal testing. 
The resulting weighted predictors were then applied to the test 
cohort to obtain per sample scores from which the area under 
the curve (AUC) was obtained using receiver operator character-
istic (ROC) analysis. R package pROC was used to calculate the 
95% CI of the AUC and also compare AUCs from two models.18 
Positive (PPV) and negative predictive values (NPV) were then 
calculated for PRS centiles, assuming different prior probabil-
ities of AS. The continuous net reclassification improvement 
(NRI),19 a statistic that aims to quantify differences in classifica-
tion performance of different models, was calculated using the 
R package PredictABEL20 and used to compare accuracy of diag-
nostic assignment by HLA- B27 testing and PRS.
RESULTS
ROC analyses of test discriminatory capacity are summarised in 
table 1. In 10- fold cross- validation in this case–control cohort, 
the PRS had AUC of 0.924 (95% CI 0.920 to 0.928) (figure 1). 
The AUC of HLA- B27 testing alone was 0.869 (95% CI 0.865 
to 0.874), which was statistically significantly less discrimina-
tory than the PRS (p<2.2×10-16). Additionally, the NRI was 
positive (0.717, 95% CI 0.692 to 0.743), confirming that the 
PRS is an improvement on HLA- B27 alone. A PRS including 
only non- MHC SNPs performed less well (AUC 0.782), as did 
a PRS including only 103 (genotyped or imputed) loci previ-
ously reported to have achieved genome- wide significance in 
AS (AUC=0.659).21 MRI has a reported sensitivity of 85% and 
specificity of 92% in AS,22 which correlates with an AUC of 
0.885. CRP has a reported sensitivity of 50% and specificity of 
80% for the disease (AUC=0.7).23
To test the performance of the PRS using external valida-
tion, the European descent cases were divided into British 
and North American cohorts, and controls divided in the 
same proportion as the two case cohorts. PRS was then 
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developed in the British training set (n=6499 cases, 12 163 
controls) and externally validated in the North American 
case–control cohort (n=1128 cases, 2111 controls). The 
PRS in the North American cohort had AUC of 0.928 (95% 
CI 0.918 to 0.939), significantly higher than HLA- B27 
alone (0.895, 95% CI 0.883 to 0.906, p=1.73×10-5) (online 
supplemental figure S1). These findings are very similar to 
the cross- validation analysis of the overall dataset reported 
above.
The PRS developed in all the European descent subjects, 
with 3994 SNPs (including 2244 major histocompatibility 
complex (MHC) SNPs), had moderate discriminatory 
capacity in East Asian, Iranian and Turkish cases and controls 
(AUC=0.788, 0.852 and 0.854, respectively), better than the 
performance of HLA- B27 alone in the Iranian and Turkish 
cohorts, but not in East Asians. In contrast, the PRS devel-
oped in East Asian subjects, then tested by cross- validation 
(i.e. also in East Asian subjects), had much better discrim-
inatory capacity (AUC=0.948, 95% CI 0.943 to 0.952) 
than did the PRS developed in European descent subjects 
when tested in East Asian subjects. The PRS involving 8659 
SNPs (including 2417 MHC SNPs) developed with all the 
East Asian subjects also performed well in European descent 
subjects (AUC=0.880, online supplemental figure S2), better 
than the discriminatory performance of HLA- B27 in each of 
the other three populations tested.
In clinical practice, the utility of all such tests depends 
on the prior probability of the disease concerned. The PPV 
and NPV of the PRS and HLA- B27 in European subjects are 
presented in figure 2 in the setting of a patient under 45 
years of age, attending a physician with a history of back 
pain for 3 months or more. Published studies report that 
in this setting the prior probability of AS is ~30%,24–26 but 
as this may vary according to referral patterns, we have 
additionally provided findings for prior probabilities of 
10% and 20% (online supplemental figures S5 and S6; East 
Asian specific findings are presented in online supplemental 
figures S7- S9). Assuming a prior probability for AS of 30%, 
Table 1 ROC analysis findings (AUC) of genetic risk scores in different populations
Predictors
Population tested in
European East Asian Iranian Turkish
HLA- B27 alone 0.869 (0.865–0.874) 0.901 (0.895–0.906) 0.831 (0.807–0.854) 0.821 (0.804–0.838)
European non- MHC PRS 0.782 (0.776–0.788)* 0.594 (0.539–0.560) 0.534 (0.500–0.569) 0.568 (0.542–0.595)
European overall PRS 0.924 (0.920–0.928)* 0.788 (0.779–0.796) 0.852 (0.826–0.879) 0.854 (0.836–0.872)
East Asian non- MHC PRS 0.555 (0.547–0.563) 0.731 (0.722–0.741)* 0.565 (0.531–0.598) 0.554 (0.528–0.581)




*10- fold cross- validation. All other PRS AUC values are external validation statistics.
AUC, area under the curve; CRP, C- reactive protein; PRS, Polygenic Risk Score; ROC, receiver operator characteristic .
Figure 1 Receiver operating characteristic curve plot of performance of Polygenic Risk Scores (PRS) (purple dashes, area under the curve 
(AUC)=0.924), HLA- B27 (aqua dashes, AUC=0.869), PRS less major histocompatibility complex (MHC) (green line, AUC=0.782) and genome- wide 
significant loci only (red line, AUC=0.659).
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an HLA- B27 test will be positive in 31% of those tested with 
a PPV of 80.6%, and in the 69% of those with a negative test, 
the NPV is 92.4%. Using the PRS, the PPV is >80.6% for 
top 35% of those screened, and achieves a higher maximum 
value (93.3%) than does HLA- B27 (80.6%) (figure 2). The 
PRS NPV will be >92.4% for 65% of those screened, and 
also achieves a higher maximum value (99.6%) than does 
HLA- B27 (92.4%). Considering the situation where only 
10% of screened patients have AS, then HLA- B27 will be 
positive in 16% of those tested. In this group, HLA- B27 
positivity has a PPV of 51.9%, and a negative result (seen 
in 84% of screened patients) has an NPV of 97.9%. Using 
the PRS, the PPV is >51.9% for 35% of patients and has a 
much higher maximum value (78.2% vs 51.9%). The NPV 
for the PRS is >97.9% for 65% of patients and achieves a 
slightly higher maximum value than HLA- B27 testing (100% 
vs 97.9%).
Considering general population screening, at least 8% 
of the European population carry HLA- B27,27 yet only 
5% of carriers of this allele will develop AS28; as such, no 
higher PPV can be achieved using HLA- B27 testing alone. In 
contrast, for the PRS, the PPV for the top 8% of the popula-
tion is three times higher (15.1%), and it is higher than 5% 
for the top 35% of the population. The NPV for HLA- B27- 
negative status is 99.9%, which is exceeded by the PRS for 
62.5% of the population.
DISCUSSION
Distinguishing AS from other causes of chronic back pain 
remains an important issue in rheumatology. HLA- B27 
testing can have a valuable PPV for AS, particularly in clin-
ical settings where the pretest probability of the disease is 
relatively high compared with the general population. It is 
therefore included in the Assessment of Spondyloarthritis 
International Study Group (ASAS) axial spondyloarthritis 
(axSpA) classification criteria and is an essential criterion 
for those with no available imaging evidence of disease. 
HLA- B27 testing has also been recommended for screening 
patients with chronic back pain to identify those at higher 
risk of AS or the related group of diseases axSpA, for 
referral to specialist services.23 25 However, HLA- B27 only 
contributes ~20% of the overall heritability of AS, which is 
estimated to be ≥90% overall, indicating a substantial non- 
MHC component.29 This suggests that PRS, which capture 
the common- variant component of heritability, are likely to 
be much more informative than HLA- B27 tests alone. Our 
study confirms this, with the PRS performing better than 
HLA- B27 testing in both AUC and continuous NRI analyses, 
irrespective of the prevalence of AS among those being tested. 
We confirm these findings both by internal cross- validation 
and by external validation. For 35% of the population, the 
PPV is higher for the PRS than for HLA- B27 testing, and 
the NPV is higher for >65%. In particular, the peak PPV 
is substantially higher for the PRS than for HLA- B27 and is 
informative for a far higher proportion of patients, as it is a 
continuous variable whereas HLA- B27 is dichotomous. PRS 
testing also has higher discriminatory capacity for AS than 
MRI, and far higher than CRP. Accurate interpretation of 
MRI scans is known to be dependent on training and expe-
rience, and particularly in inexperienced, untrained hands 
may perform worse than the average reported performance, 
in which setting PRS may be particularly valuable.
Chronic back pain of >3 months’ duration has previ-
ously been shown to have very low heritability attributable 
to common genetic variants (minor allele frequency >0.01) 
such as those included in our AS PRS (common variant 
heritability=6.43%30–7.6%31) and not to be genetically 
correlated with AS. Therefore, it is unlikely that the AS 
Figure 2 Positive (PPV) and negative predictive values (NPV) of Polygenic Risk Scores (PRS) and HLA- B27 for ankylosing spondylitis (AS), assuming 
prior probability of AS of 30%, among Europeans. Centiles refer to the population distribution of the PRS.
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PRS will prove less discriminatory in practice in the clinical 
setting of patients presenting with chronic back pain than 
the estimates presented here. A limitation of this study is 
that the performance of the PRS has not been formally tested 
in this setting, where it will require further evaluation.
axSpA refers to a spectrum of diseases. Patients with 
radiographic sacroiliitis are classified as having AS, whereas 
those without X- ray changes are classified as having non- 
radiographic (nr)- axSpA. The current PRS may have prog-
nostic value in distinguishing the 16%–24% of nr- axSpA 
cases that are likely to go on to develop AS.32 33 Whether 
the PRS we report here will prove more informative than 
HLA- B27 testing alone in patients with nr- axSpA itself is 
unknown. The ASAS have previously demonstrated that 
patients meeting the ASAS classification criteria for axSpA 
who do not yet have AS have a much lower average genetic 
risk score than patients with AS, using only genome- wide 
significant AS loci.34 Whether this is because nr- axSpA 
is actually genetically distinct from AS, or reflects the 
greater clinical and likely aetiopathogenic heterogeneity of 
nr- axSpA,35 will require further study.
As with the use of PRS in the screening of individuals with chronic 
back pain, its performance in nr- axSpA will also require further 
study. Similarly, the performance of the PRS in males compared with 
females, in subjects with environmental risk factors for the disease 
such as cigarette smoking,36 and in subsets of patients such as those 
with extraskeletal manifestations of AS requires further study. In that 
regard, the excellent performance of a PRS in patients with acute 
anterior uveitis complicating AS (AUC=0.96; 95% CI 0.955 to 
0.966) suggests that at least in some AS subsets the performance of 
the PRS will be even better than reported here.37
PRS testing can be performed using data from any dense 
SNP microarray. Indeed, the performance of the PRS reported 
here was high despite our use of a relatively low density SNP 
microarray—the Illumina Core- Exome chip (>520 000 variants, 
including many rare and non- polymorphic variants that do not 
contribute to the PRS). The performance of PRS testing would 
be likely to improve further with use of microarrays with better 
SNP coverage, or with whole genome sequencing. It has been esti-
mated that up to 12 million Americans have had SNP microarray 
testing performed by commercial services such as 23andMe and 
Ancestry.38 At little additional cost, these data would probably 
prove suitable for the calculation of the AS PRS we report, as 
well as enabling PRS for many other diseases in which they have 
been shown to be informative. The cost- effectiveness of the PRS 
we report here needs to be confirmed in further studies. As the 
genetic profile of AS becomes better understood, the discrimina-
tory capacity of these tests is also likely to increase. For example, 
it is likely that many of the SNPs included in the PRS at present 
are not truly associated with AS, but just add noise to the test.
As there is no preventive therapy yet for AS, general popula-
tion screening to identify patients at high risk of the disease is 
not recommended except, perhaps, for those at increased risk, 
such as the relatives of those with AS (given the high sibling 
recurrence risk of 8.2%).39 PRS performs significantly better 
than HLA- B27 testing alone in the general population, with the 
PPV of the ~8% of the general population who carry HLA- B27 
being 5%, compared with the peak PPV of the PRS of 15.1%. 
Similarly, the NPV for the PRS exceeds that of HLA- B27 testing 
for most of the population. Although the PPV for PRS testing for 
general population screening is modest, the test performs well 
compared with other widely used screening tests. For example, 
the PPVs for 10- year risk of coronary heart disease of a high 
total cholesterol (≥240 mg/dL)—a threshold above which many 
patients will be prescribed cholesterol- lowering therapy—are 
10.3% in women and 18.6% in men,40 similar to the top 20% 
of PPVs of PRS for AS in general population screening. Among 
those who have already had SNP microarray testing performed, 
knowledge of a high AS- PRS even in the absence of symptoms 
may heighten clinician awareness of the possible diagnosis, 
reduce delay and assist with earlier appropriate and effective 
treatment, given the current long diagnostic delays.
Our study shows that the performance of the PRS varies 
between ethnic groups, although it remains moderately high 
even when a PRS developed in subjects of (western) European 
descent is tested in eastern European/west Asian subjects such 
as Turks and Iranians. The PRS developed specifically for East 
Asians performed far better in that population than did the 
European PRS, indicating that at least for populations that are 
remotely related, ethnic- specific PRSs are preferable.
We conclude that PRS testing for AS has greater discrimi-
natory capacity than HLA- B27 testing, MRI scanning or CRP 
testing, either alone or in combination. PRS could be used to 
screen patients with chronic back pain to identify subjects at 
increased risk of the disease for referral to secondary care and to 
assist in diagnosing the condition.
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Table S1  Case-control cohorts studied.  AS=ankylosing spondylitis.  Gender is as imputed from SNP 
array data. 





AS United Kingdom AS Cohort 
1






751 377 1128* 24v1-1 
AS Australian AS Cohort 
3
 333 92 425* 24v1-0, 24v1-1 
AS Groupe Française d'Etude 




123 69 192*  
AS Chinese AS cohort 
3
 4786 1215 6001◦ 24v1-1 
AS Turkish AS cases 
4
 668 239 910 24v1-0 
AS Iranian AS cases 
4
 336 92 430 24v1-0 




4178 5283 9469* 12v1 
Controls Queensland Institute of Medical 
Research Berghofer Medical 
Research Institute Twins Cohort 
2
 
1006 1655 2664* 12v1 
Controls Advancing Exercise & Sports 
Science Collaborative Research 
765 734 1504* 24v1-1 
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Controls Oregon Metagenomics Controls 
5
 
38 44 82* 24v1-1 




291 264 555* 24v1-0, 24v1-1 




3159 1784 4943◦ 24v1-0 




661 258 924 24v1-0 




590 164 761 24v1-0, 24v1-1 
 
* Included in European-descent cohort. 
◦ Included in East Asian cohort 
Please note that as for some sample’s imputation did not assign gender definitively, the total sample 
number may differ from the sum of the numbers of males and females.  
 
1. The UK AS Cohort was recruited from patients attending hospital-based rheumatology 
services across the United Kingdom.   Rheumatology specialists caring for the patients 
confirmed the diagnosis of AS according to the modified New York Criteria for AS.   Pelvic 
radiographs were reported by local expert readers. 
2. Australo-Anglo-American Spondyloarthritis Consortium cohort was recruited from patients 
attending hospital-based rheumatology services in Australia and the United States.   
Rheumatology specialists caring for the patients confirmed the diagnosis of AS according to 
the modified New York Criteria for AS.   Pelvic radiographs were centrally reported by expert 
readers. 
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3. The Australian AS cohort was recruited from patients attending rheumatology services (both 
hospital based and from community rheumatology practices) in Australia.   Rheumatology 
specialists caring for the patients confirmed the diagnosis of AS according to the modified 
New York Criteria for AS.   Pelvic radiographs were centrally reported by expert readers. 
4. The Groupe Française d'Etude Génétique des Spondylarthrites (GFEGS) was recruited from 
hospital-based rheumatology services in France. Rheumatology specialists caring for the 
patients confirmed the diagnosis of AS according to the modified New York Criteria for AS.   
Pelvic radiographs were reported by local expert readers. 
5.  The Chinese AS Cohort was recruited from self-reporting Han Chinese ethnicity patients 
attending hospital-based rheumatology services in China and Taiwan.  Rheumatology 
specialists caring for the patients confirmed the diagnosis of AS according to the modified 
New York Criteria for AS. Pelvic radiographs were reported by local expert readers. 
6. The Turkish and Iranian AS Cohorts were recruited from patients attending hospital-based 
rheumatology services in Turkey and Iran respectively.  Rheumatology specialists caring for 
the patients confirmed the diagnosis of AS according to the modified New York Criteria for 
AS. Pelvic radiographs were reported by local expert readers. 
 
Supplementary Method 
Genotyping Chips and Quality Control 
The cohorts were all typed on Illumina Core-Exome chip. The chip versions used are 24v1-1, 24v1-0, 
12v1 and 12v1. The number of overlapping SNPs among these chips is greater than 95%.  All the data 
were called separately based on the Core-Exome chip versions from GenomeStudio 2.0.  Ethnicity-
specific data was strand fixed based on the chip version. The ethnicity-specific datasets were then 
merged into a European-descent cohort and an East Asian cohort using the common SNPs between 
datasets.  Then normal GWAS quality control was applied to all the cohorts in this study.  Related 
samples (PI_HAT >0.185) were excluded.  Samples were further excluded if their missingness rate 
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was >5%, or heterozygosity > 3 standard deviations from mean, or were outliers in the principal 
component analysis (by SHELLFISH).  Variants were excluded if their missingness rate was >2%, or 
Hardy-Weinberg equilibrium test P-value < 1x10
-6
, or they have significant different missingness rate 




Confidence interval of AUC 
The confidence interval of AUC was calculated by R package pROC. 
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Table S2 Performance of HLA-B27 and AS PRS with controlling PCA and sex.    
 Population tested in 






















































PCA alone – European 0.630 - - - 
PCA alone – East Asian - 0.750 - - 
PCA alone – Iranian - - 0.536  
PCA alone – Turkish - - - 0.520 
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Figure S1:  Receiver operating characteristic curve plot of performance of HLA-B27 in the North 
American cohort (red line, AUC=0.895), PRS trained in the British cohort and externally validated in 
the North American cohort (aqua line, AUC=0.928), and European PRS cross-validated (purple line, 
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Figure S2:  Receiver operating characteristic curve plot of performance of PRS in European-descent 
cohort (purple line, AUC=0.924 based on 10 folds cross-validation) and East-Asian cohort (red 
dotted, AUC=0.948 based on 10 folds cross-validation). The validation performance of the European 
PRS in different cohort are shown in solid line (Iranian (green, AUC=0.852), Turkish (blue line, 
AUC=0.854), East Asian (red, AUC=0.788)) whilst the validation performance of the East-Asian PRS in 
other population are in dotted lines (Iranian (green, AUC=0.872), Turkish (blue, AUC=0.840), 
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Figure S3: Positive and negative predictive values of PRS for AS in Europeans, assuming prior 
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Figure S4: Positive and negative predictive values of PRS for AS in Europeans, assuming prior 
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Figure S5: Positive and negative predictive values of PRS for AS in Europeans, assuming prior 
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Figure S6:  Positive and negative predictive values of PRS for AS in East Asian cohort, assuming prior 
probability of AS of 0.55% (the population prevalence of AS).    
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Figure S7: Positive and negative predictive values of PRS for AS in East Asian cohort, assuming prior 
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Figure S8: Positive and negative predictive values of PRS for AS in East Asian cohort, assuming prior 
probability of AS of 20%.    
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Figure S9: Positive and negative predictive values of PRS for AS in East Asian cohort, assuming prior 
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Figure S10. Scheme of analysis.  A. Analysis flow-chart. B. Scheme of 10 folds cross-validation in EUR 
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Figure S11.  Principal coordinates analysis plot of PC1 vs PC2 in European-descent cases and controls, 
compared with ancestry-known subjects from HapMap3.   AFR=African, AMR=Admixed American 
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Figure S12.  Principal coordinates analysis plot of PC1 vs PC2 in East Asian-descent cases and 
controls, compared with ancestry-known subjects from HapMap3.   AFR=African, AMR=Admixed 
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Figure S13:  Principal coordinates analysis plot of PC1 vs PC2 in Iranian cases and controls, compared 
with ancestry-known subjects from HapMap3.   AFR=African, AMR=Admixed American (Mexican 
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Figure S14:  Principal coordinates analysis plot of PC1 vs PC2 in Turkish cases and controls, compared 
with ancestry-known subjects from HapMap3.   AFR=African, AMR=Admixed American (Mexican 
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